肝细胞癌针吸活检的肿瘤种植:一项系统综述
该系统综述评估肝细胞癌活检的肿瘤种植风险,排除非肝癌及干预后种植。共纳入37项研究、13959次活检,种植率为0.62%(范围0%-7.77%),报告的中位随访时间平均为35.8个月(范围10.5-60个月)。总体而言,肝细胞癌活检的肿瘤种植风险低。
要点
- 肝细胞癌活检的肿瘤种植率为0.62%(范围0%-7.77%)。
- 共纳入37项研究、13959次活检。
- 报告的中位随访时间平均为35.8个月(范围10.5-60个月)。
核心结论
- 总体而言,肝细胞癌活检的肿瘤种植风险低。
研究设计与样本
- 系统综述,评估肝细胞癌活检的肿瘤种植风险,排除非肝癌及干预后种植。
- 共识别2339篇唯一摘要,最终纳入37项研究。
主要发现
- 13959次活检的肿瘤种植率为0.62%(范围0%-7.77%)。
- 报告的中位随访时间平均为35.8个月(范围10.5-60个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Biopsy of hepatocellular carcinoma (HCC) may help with selecting appropriate chemotherapy with inconclusive imaging; concern about potential seeding may limit its use. METHODS: A systematic review was conducted to assess the risk of tumor seeding with biopsy of HCC excluding nonliver cancers or seeding after interventions. RESULTS: A total of 2,339 unique abstracts were identified; 37 studies were included in the final analysis. The rate of tumor seeding was 0.62% (range 0%-7.77%) in 13,959 biopsies performed. The average reported median lengths of follow-up was 35.8 months (range 10.5-60 months). DISCUSSION: Overall, the risk of tumor seeding with biopsy of HCC is low.
引用
- Nie C, Vaska M, Wong JK, et al. Tumor Seeding With Needle Biopsy of Hepatocellular Carcinoma: A Systematic Review. Am J Gastroenterol. 2024. PMID: 39692333. doi:10.14309/ajg.0000000000003210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。